Cryoport Systems’ IntegriCell® Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
IntegriCell will provide process development, technology transfer, and clinical cryopreservation services for Verismo’s SynKIR™-110 and SynKIR™-310 programs.
Cryoport Systems is pleased to share that Verismo Therapeutics has selected IntegriCell® cryopreservation services to support two clinical KIR-CAR T cell therapy programs: SynKIR™-110, currently being evaluated in the STAR-101 Phase 1 trial for patients with advanced mesothelin-expressing solid tumors, and SynKIR™-310, currently being evaluated in the CELESTIAL-301 Phase 1 trial for patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Both candidates are in human clinical trials, with initial Phase 1 data presented at the AACR 2026 Annual Meeting.
For clinical-stage cell therapy developers, advancing a program often means finding the right balance between continuity and scale. Existing processes must be protected, especially when they are already embedded in regulatory work, while new controls and infrastructure are introduced to support the next stage of growth. That is where IntegriCell is designed to add value.
Through this collaboration, Verismo worked with Cryoport Systems to transfer their cryopreservation process into IntegriCell’s globally standardized, GMP-compliant infrastructure. The work includes technology transfer, process development support, and clinical cryopreservation services intended to help Verismo maintain its established workflow while improving process control and long-term scalability.
Technology transfer is not simply a handoff. In cell therapy, it can require detailed alignment across process parameters, materials, documentation, quality expectations, and operational execution. For developers working with sensitive biological materials and evolving clinical timelines, the transfer process must be handled with care and precision.
Verismo’s programs are based on its novel multi-chain KIR-CAR platform, which is designed to address high unmet needs in advanced solid tumors and B cell associated disorders and malignancies. As its lead programs continue through Phase 1 clinical development, Verismo needed a partner that could work within its existing cryopreservation workflow rather than requiring unnecessary disruption.
Bryan Kim, CEO and Co-Founder of Verismo Therapeutics, emphasized that cryopreservation is an important part of the manufacturing process and that a partner with the expertise to operate within Verismo’s existing workflow was essential. He also noted that the IntegriCell team implemented Verismo’s process with precision and worked alongside Verismo to identify opportunities to improve process control and long-term scalability.
“Advancing a cell therapy program requires a partner that can help developers refine and scale critical processes as their programs mature,” said Dr. Mark Sawicki, CEO, Cryoport Systems.
IntegriCell cryopreservation service centers are located in Houston, Texas and Liège, Belgium, providing geographic coverage to support clinical and commercial programs across the Americas and Europe. These capabilities connect to Cryoport Systems’ broader temperature-controlled supply chain platform, including logistics, BioServices and biostorage, and consulting and advisory support. For developers preparing for larger trials, additional geographies, or eventual commercial readiness, that integration can reduce the complexity of managing critical materials across multiple providers. It also gives teams a more connected path from cryopreservation through storage and distribution.
Cryoport Systems is proud to support Verismo Therapeutics as it advances its SynKIR™-110 and SynKIR™-310 programs and continues developing its KIR-CAR platform.
